Prevalence of Metabolic Syndrome in Patients With Clinically Advanced Peripheral Vascular Disease

Qadan, Laila; Ahmed, Aftab; Safar, Hussein A.; Al-Bader, Marzouk A.; Ali, Amr

doi:10.1177/0003319707304582

Cited by 15 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 For Spanish patients with established cardiovascular disease, the prevalence of MS is 37%, 21,22 which is also lower than the rate measured in our study. This could be due to the fact that patients with PAD have a greater burden of risk factors than patients who have ischemic heart disease or cerebrovascular disease (as revealed in the REACH study 23 ).…”

Section: Discussioncontrasting

confidence: 69%

Metabolic syndrome in patients with peripheral arterial disease

Estirado

Lahoz

Laguna

et al. 2014

Revista Clínica Española (English Edition)

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 69%

Metabolic syndrome in patients with peripheral arterial disease

Estirado

Lahoz

Laguna

et al. 2014

Revista Clínica Española (English Edition)

View full text Add to dashboard Cite

“…Qadan et al reported that the prevalence of metabolic syndrome was more than 95% in patients with advanced PAD, and that DM was the most prevalent component followed by hypertension and low HDL cholesterol. 12 In the FRENA registry, it was found that the patients with PAD showed an inverse correlation between BMI and cardiovascular mortality. 13 In the present study, the BMI of patients with PAD was lower than that of patients without PAD.…”

Section: Risk Factorsmentioning

confidence: 99%

Preventive Effects of Eicosapentaenoic Acid on Coronary Artery Disease in Patients With Peripheral Artery Disease - Subanalysis of the JELIS Trial -

Ishikawa¹,

Yokoyama

Saitō

et al. 2010

Circ J

View full text Add to dashboard Cite

he Japan eicosapentaenoic acid (EPA) lipid intervention study (JELIS) was the first large-scale randomized trial that examined the preventive effects of EPA in patients with hypercholesterolemia at risk of developing coronary artery disease (CAD). A major finding of JELIS was that EPA at the daily dose of 1,800 mg significantly reduced the incidence of major coronary events (MCE) by 19% (hazard ratio 0.81, 95% confidence interval (95%CI) 0.69-0.95, P=0.011). 1 The subanalysis of JELIS showed that EPA reduced the incidence of recurrent stroke. 2 In the primary prevention group, EPA also reduced the incidence of CAD in the high-risk group. 3 Editorial p 1298Among atherosclerotic risk factors, age and total cho-

show abstract

“…Atherosclerotic vascular diseases (especially CAD and stroke) are common in Arab countries, undoubtedly due to the high prevalence of dyslipidemia and diabetes singly or jointly as in MetS [13,14]. It is essential to investigate how all these latter factors interact with the high prevalence of hyperuricemia in individuals who are already at high risk for CAD.…”

Section: Introductionmentioning

confidence: 99%

Determinants of Blood Uric Acid Levels in a Dyslipidemic Arab Population

Al-Meshaweh

Jafar²,

Asem³

et al. 2011

Med Princ Pract

View full text Add to dashboard Cite

Objectives: The objective of this study was to explore the relationships between circulating uric acid and lipid levels and components of the metabolic syndrome (MetS) in Arab dyslipidemic patients, a group already at high coronary artery disease risk. Subjects and Methods: The medical records of 1,229 subjects (632 men, 597 women) referred for treatment of dyslipidemia and followed up for at least 12 months were reviewed. Serum levels of uric acid and lipids (total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein) and other variables in the National Cholesterol Education Program ATP III criteria definition of MetS were assessed at initial presentation and every 4– 6 months, under specific lipid-lowering treatment (statins and/or fibrates), in each of the subjects. Their respective associations were explored by appropriate logistic regression techniques with control for confounding risk factors, including age, gender and body mass index. Results: 306 subjects (24.9%) of the study population were hyperuricemic; they were more likely to be men, obese and diabetic. Also the serum uric acid level (mean ± SD) was greater in men with MetS compared with men without (377.0 ± 98.0 vs. 361.6 ± 83.1 µmol/l, p < 0.05), an observation not reproduced in women. Uric acid levels had significant associations with the presence of fasting hyperglycemia, hypertension and large waist circumference (WC) in men, but only with large WC in women. With statin treatment, uric acid levels decreased by 10% within 1 year of treatment; with fibrates, uric acid levels remained unchanged or slightly increased. Conclusion: The data showed that hyperuricemia is common in dyslipidemic patients in Kuwait, where its important determinants are male sex, obesity, diabetes and statin treatment.

show abstract

Prevalence of Metabolic Syndrome in Patients With Clinically Advanced Peripheral Vascular Disease

Cited by 15 publications

References 40 publications

Metabolic syndrome in patients with peripheral arterial disease

Metabolic syndrome in patients with peripheral arterial disease

Preventive Effects of Eicosapentaenoic Acid on Coronary Artery Disease in Patients With Peripheral Artery Disease - Subanalysis of the JELIS Trial -

Determinants of Blood Uric Acid Levels in a Dyslipidemic Arab Population

Contact Info

Product

Resources

About